ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

摘要:

Although psoriasis is perceived to have a limited effect on the cost of US healthcare, the reality is very different. Psoriasis is a persistent and progressive skin disorder that affects about 6 million people in the US, with 250 000 new cases diagnosed every year. Depending on disease severity, annual outpatient care can cost $US1400-$US6600 per patient, representing a total national cost of $US3.2 billion/year in the US. According to investigators from Health Economics Research, New Jersey, US, the high cost of care for selected patients with mild-to-moderate psoriasis can be reduced by using the new topical retinoid tazarotene. At the recent 56th Annual Meeting of the American Dermatology Association [Orlando, US; Mar 1998], the investigators presented the results of a pharmacoeconomic model of monotherapy with either tazarotene, fluocinonide or calcipotriol for patients with mild-to-moderate stable plaque psoriasis.*

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

摘要:

After waiting in the wings for more than 10 years, monoclonal antibodies are finally finding a place on the clinical stage for the treatment of various cancers. Researchers at the 11th International Conference on Monoclonal Antibodies for Cancer [California, US; March 1998] introduced the latest stars entering the market, as well as promising candidates now entering clinical trials.

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS